Literature DB >> 15781816

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

M Tiberio1, D T Chard, D R Altmann, G Davies, C M Griffin, W Rashid, J Sastre-Garriga, A J Thompson, D H Miller.   

Abstract

BACKGROUND: Brain atrophy, in excess of that seen with normal aging, has been observed early in the clinical course of relapsing-remitting multiple sclerosis (RRMS). Previous work has suggested that at this stage of the disease, gray matter (GM) atrophy progresses more rapidly than the white matter (WM) atrophy.
OBJECTIVES: To characterize the evolution of GM and WM volumes over 2 years, and their associations with lesion loads in a cohort of patients with clinically early RRMS.
METHODS: Twenty-one patients with RRMS (mean age 37.5 years, mean disease duration from symptom onset 2.1 years) and 10 healthy control subjects (mean age 37.1 years) were studied. Tissue volumes, as fractions of total intracranial volumes, were estimated at baseline and 1- and 2-year follow-up. Brain parenchymal fractions (BPF), GM fractions (GMF), and WM fractions (WMF) were estimated. In subjects with MS, brain lesion loads were determined on conventional T2-weighted along with pre- and post-gadolinium (Gd) enhanced T1-weighted images at each timepoint.
RESULTS: A decrease in GMF was observed in subjects with MS vs normal controls over the 2 years of the study (mean -2.1% vs -1.0%, p = 0.044), while no change was seen in WMF over the same period (mean -0.09% vs +0.09%, p = 0.812). However, when the MS cohort was divided in half, dependent upon change in Gd-enhancing lesion load over 2 years (n = 20), a decrease in WMF was seen in the group (n = 10) with the largest decline in Gd volume, whereas WMF increased in the other half (n = 10) concurrent with a net increase in volume of Gd-enhancing lesions (difference between groups: p = 0.034).
CONCLUSIONS: Increasing gray matter but not white matter (WM) atrophy was observed early in the clinical course of relapsing-remitting multiple sclerosis. Fluctuations in inflammatory WM lesions appear to be related to volume changes in WM over this time period.

Entities:  

Mesh:

Year:  2005        PMID: 15781816     DOI: 10.1212/01.WNL.0000154526.22878.30

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

1.  Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.

Authors:  P G Sämann; M Knop; E Golgor; S Messler; M Czisch; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

Review 2.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS.

Authors:  Marco Rovaris; Elda Judica; Antonia Ceccarelli; Angelo Ghezzi; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 4.  Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.

Authors:  Elisabetta Vegeto; Valeria Benedusi; Adriana Maggi
Journal:  Front Neuroendocrinol       Date:  2008-04-29       Impact factor: 8.606

Review 5.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

6.  Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects.

Authors:  Kerstin Bendfeldt; Louis Hofstetter; Pascal Kuster; Stefan Traud; Nicole Mueller-Lenke; Yvonne Naegelin; Ludwig Kappos; Achim Gass; Thomas E Nichols; Frederik Barkhof; Hugo Vrenken; Stefan D Roosendaal; Jeroen J G Geurts; Ernst-Wilhelm Radue; Stefan J Borgwardt
Journal:  Hum Brain Mapp       Date:  2011-04-29       Impact factor: 5.038

Review 7.  Cortical lesions in multiple sclerosis.

Authors:  Massimiliano Calabrese; Massimo Filippi; Paolo Gallo
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

8.  Relevance of the skewness index in DTI exploration of multiple sclerosis.

Authors:  Eliane Graulières; Jean-Albert Lotterie; Emmanuelle Cassol; Angélique Gerdelat; Michel Clanet; Isabelle Berry
Journal:  MAGMA       Date:  2008-11-08       Impact factor: 2.310

Review 9.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

Review 10.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.